Skip to main content

Protalix BioTherapeutics, Inc. (PLX)

NYSEAMERICAN: PLX · IEX Real-Time Price · USD
0.813 -0.037 (-4.31%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap37.06M
Revenue (ttm)49.30M
Net Income (ttm)-20.52M
Shares Out45.56M
EPS (ttm)-0.50
PE Ration/a
Forward PE111.11
Dividendn/a
Ex-Dividend Daten/a
Volume519,241
Open0.851
Previous Close0.850
Day's Range0.790 - 0.890
52-Week Range0.790 - 7.020
Beta2.51
AnalystsBuy
Price Target9.00 (+1,006.5%)
Earnings DateNov 15, 2021

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form...

IndustryBiotechnology
IPO DateMay 15, 1998
CEODror Bashan
Employees207
Stock ExchangeNYSEAMERICAN
Ticker SymbolPLX
Full Company Profile

Financial Performance

In 2020, PLX's revenue was $62.90 million, an increase of 15.00% compared to the previous year's $54.69 million. Losses were -$6.52 million, -64.31% less than in 2019.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PLX stock is "Buy" and the 12-month stock price forecast is 9.00.

Price Target
$9.00
(1,006.47% upside)
Analyst Consensus: Buy

News

Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update

CARMIEL, Israel, Nov. 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

2 weeks ago - PRNewsWire

Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update ...

CARMIEL, Israel, Nov. 8, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

3 weeks ago - PRNewsWire

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE C...

CARMIEL, Israel and BOSTON, Oct. 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerci...

1 month ago - PRNewsWire

Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fa...

CARMIEL, Israel and BOSTON, Oct. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerci...

1 month ago - PRNewsWire

Protalix BioTherapeutics Announces Closing of Private Note Exchange

CARMIEL, Israel, Aug. 26, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

3 months ago - PRNewsWire

Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update

CARMIEL, Israel, Aug. 16, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

3 months ago - PRNewsWire

Protalix BioTherapeutics Announces Private Note Exchange

CARMIEL, Israel, Aug. 13, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

3 months ago - PRNewsWire

Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update...

CARMIEL, Israel, Aug. 9, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

3 months ago - PRNewsWire

Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application

Protalix BioTherapeutics Inc (NYSE: PLX) has submitted a Type A Meeting request to the FDA regarding PRX-102 Complete Response Letter it received in April. The FDA issued the response letter for pegunig...

4 months ago - Benzinga

Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA

CARMIEL, Israel, Aug. 2, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

4 months ago - PRNewsWire

Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021

CARMIEL, Israel , June 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of...

5 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such inves...

5 months ago - Newsfile Corp

Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Farmaceutici S.p.A. have provided an update on the clinical development of pegunigalsidase alfa (PRX–102) for the proposed treatment of Fabry disease.

6 months ago - Benzinga

Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for...

CARMIEL, Israel and BOSTON, June 2, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercia...

6 months ago - PRNewsWire

Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update

CARMIEL, Israel, May 14, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

6 months ago - PRNewsWire

Earnings Preview for Protalix BioTherapeutics

On Friday, May 14, Protalix BioTherapeutics (AMEX:PLX) will release its latest earnings report. Here is Benzinga's outlook for the company.

6 months ago - Benzinga

Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021

CARMIEL, Israel, May 7, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of ...

6 months ago - PRNewsWire

Why Protalix BioTherapeutics Stock Is Plunging Today

Investors did not like the company's latest regulatory update.

7 months ago - The Motley Fool

Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA

CARMIEL, Israel, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization o...

7 months ago - PRNewsWire

PLX Stock: Why Protalix BioTherapeutics Is Plunging 40% Today

An update from Protalix BioTherapeutics shows how a disappointing FDA decision can roil a biotech name like PLX stock. The post PLX Stock: Why Protalix BioTherapeutics Is Plunging 40% Today appeared fir...

7 months ago - InvestorPlace

Protalix Stock Falls After FDA Slaps CRL For PRX-102 Application In Fabry Disease

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici, have received a Complete Response Letter (CRL) from the FDA related to the marketing app...

7 months ago - Benzinga

Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa fr...

CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercia...

7 months ago - PRNewsWire

Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results

CARMIEL, Israel, March 30, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization ...

8 months ago - PRNewsWire

Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021

CARMIEL, Israel, March 22, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization ...

8 months ago - PRNewsWire

Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

CARMIEL, Israel, March 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

9 months ago - PRNewsWire